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ABSTRACT
Elucidating mechanisms that drive drug craving is crucial to develop pharmacological
interventions for addiction. Repeated exposure to psychostimulants produces an enhanced
behavioral and neurochemical sensitivity to both the drug and drug-related cues, known as
sensitization. We hypothesize that VMAT, the protein responsible for storage of dopamine (DA)
into the vesicles, may be functionally altered to redistribute DA between the cytoplasmic pool and
the vesicular pool based on demands for drug-mediated release versus neurotransmission in the
context of conditioned environmental cues. To examine the role of VMAT, we pretreated rats with
a VMAT blocker, tetrabenazine (TBZ), before each daily treatment of a regimen of seven
amphetamine (AMPH) injections and subsequently tested for the blockade of psychomotor
sensitization. Two behavioral approaches were implemented to examine the role of VMAT in
mediating behavioral sensitization, Aim 1) AMPH evoked behavior and Aim 2) electrically evoked
behavior, because these behaviors reflect different mechanisms that are known to become
sensitized. In Aim 1), rats were previously prepared with unilateral striatal DA-depletions using
6-OHDA infused into the medial forebrain bundle. After the 7-day Induction Phase, rats were
tested for expression of sensitization or its blockade by TBZ by measuring AMPH-evoked
rotational behavior. In Aim 2), rats with electrode implants into the MFB that produced electrically
stimulated rotational behavior (ESRB), underwent an induction phase and an expression phase as
in Aim 1, except that ESRB was tested for sensitization or blockade by TBZ. Within Subjects
comparisons from the Induction Phase corroborate expression phase of sensitization and acute
effects of TBZ. Between Subjects comparisons from the Expression Phase also demonstrated
sensitization of both AMPH-evoked rotational behavior and ESRB. Additionally, these data show
that sensitization was blocked in both pharmacokinetic driven and exocytotic-like driven behaviors
by TBZ pretreatment. VMAT may sensitize AMPH-evoked responses and behavior evoked by
environmental stimuli that activate endogenous neural communication. Future research must
evaluate the effects of VMAT blockade during AMPH exposure upon DA overflow/exocytosis
and investigate potential pharmacotherapeutic interventions that target VMAT function.
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INTRODUCTION
Substance abuse disorder affects 53.2 million people in the US, with illicit drugs such as marijuana,
cocaine and amphetamines (AMPH) affecting 1 in 5 individuals age 12 and older (SAMHSA,
2018). Furthermore, in 2017 addiction treatment cost the US more than $740 billion a year in legalcrime related costs, loss of work productivity, and healthcare expenses (NIDA, 2017). Drug
addiction is a disease that is characterized by a substance abuse dependence in which a person
seemingly cannot escape a vicious cycle. The DSM V defines substance use disorder based on the
following 11 criteria: 1) Taking large amounts of the drug, 2) Wanting to cut or reduce drug but
not managing to, 3) Spending time getting, using or recovering from drug use, 4) Craving and
urges to use substance, 5) Inability to continue with normal life responsibilities, 6)Continue use
that causes relationship issues, 7) Giving up important social activities due to substance use, 8)
Continued drug use even when it puts you in danger, 9) Continuing to use even with knowledge
of physical and psychological problem made worse by the drug, 10) Developing tolerance to drug,
11) Developing of withdrawal symptoms, that are relieved after drug intake. The amount of time
spent seeking access and using a substance, including recidivism, is believed to be due largely to
craving. Robinson and Berridge (2001) attribute wanting, or craving, of a stimulant drug to
sensitization. Therefore, this proposal aims to explore one potential presynaptic mechanism that
may regulate the sensitized overflow of dopamine (DA) in response to a drug challenge or in
response to environmental cues, the latter presumably reflecting mechanisms of Pavlovian
conditioning, in animals with a history of AMPH exposure. An important feature of stimulant drug
addiction is sensitization, which is the process by which repeated exposure to the same dose of a
psychostimulant produces an enhanced response at the behavioral level and at the level of
dopaminergic mesotelencephalic systems (Robinson & Becker, 1996).
1

Dopamine Exocytosis Versus Amphetamine Evoked Overflow
DA can be “released” via two mechanisms.

First, exocytosis describes endogenous events

triggered by environmental stimuli such that during normal neurotransmission DA is released from
vesicles. A key concept, to be addressed below, is that DA is previously stored into vesicles by the
protein Vesicular Monoamine Transporter (VMAT) before exocytosis. Initially, an action potential
that is triggered by external stimuli (e.g., cues in the world that predict an event or availability of
drug) travels down the axon, and the depolarization by the action potential that occurs at the
terminal bouton opens calcium (Ca++) channels. Ca++ will enter the neuron, activating vesicles to
dock with the cell membrane and release DA into the synapse.
The second mechanism involves the pharmacological mechanism of action by AMPH at the level
of the presynaptic dopamine transporter (DAT). In the synapse, AMPH is transported into the
intraneuronal cytoplasmic compartment while simultaneously reversing the function of DAT,
resulting in transport of DA from the cytoplasmic compartment into the extracellular space in an
exchange-diffusion mechanism (Fischer & Cho, 1979; Raiteri et al., 1979). In a similar manner,
AMPH in the cytoplasm subsequently displaces vesicularly stored DA into the cytoplasmic DA
pool at the locus of VMAT (Fleckenstein & Hanson, 2013; Sulzer et al.; 2005). This augmentation
in the cytoplasmic pool of DA is thought to further enhance overflow through DAT.
Research on stimulant-induced sensitization has particularly focused on mesotelencephalic DA
pathways. The nigrostriatal pathway mediates movement, and it projects from the substantia nigra
to the neostriatum. The mesolimbic pathway is involved in reward and motivation and it projects
from the ventral tegmental area to the nucleus accumbens. Lastly, the mesocortical pathway is
involved in executive function and it projects from the VTA to the prefrontal cortex (Adinoff,
2004; Taber et al., 2012; Wise, 2009). Previous research has shown sensitizing effects of
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stimulants upon these three DA systems (Taylor et al., 2013; Steidl et al., 2017; Kopra et al., 2019;
Siciliano et al., Kawa et al., 2016; Kawa & Robinson, 2019). In this study, we take advantage of
the sensitizing effects upon locomotion, which is well-established as being mediated by the
nigrostriatal system, and we use this to model neural sensitization of DA neurons in general,
regardless of whether they are substrates of the nigrostriatal, mesolimbic or mesocortical
pathways.
Clinical Literature on Sensitization
Sensitization of behavior has been shown in clinical settings where naïve subjects who repeatedly
received a low dose of AMPH showed a transition in response from an initial euphoria,
subsequently exhibiting paranoia and finally manifesting psychotic- or manic-like symptoms
(Strakowski et al. 1996). The transition from euphoria to psychotic-like responses in response to
repeated stimulant drug exposure has been extensively reported in the literature (Kenji &
Strakowski, 2001; Griffith et al. 1968). Stereotypical behaviors such as repeated head movements,
eye-blinking and increases in speech have been observed in humans after repeated AMPH
exposure (Strokovski et al., 1996). Most significantly, sensitization of incentive motivational brain
systems (i.e., mesolimbic) is likely responsible for the highly addictive effects of stimulant drug
use and the incessant recidivism (Robinson & Berridge, 2001).
Previous research has also shown a relationship between repeated drug exposure and Pavlovian
Conditioning, where subjects suffering from substance abuse disorder associate drug paired
environmental stimuli with the physiological and pharmacological effects of stimulant drug. These
context-related environmental cues are related to craving and drug seeking behaviors (Kalivas and
Volkow, 2005). In the absence of the pharmacological effects of AMPH, Discriminant Cues
activate endogenous neurotransmission to produce exocytosis of DA. Thus, there is a sensitization
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that may reflect principles of Classical Conditioning, which play an important role in craving and
consequent relapse (Hyman, Malenka & Nestler, 2006; Kauer, 2004).
AMPH-evoked sensitized responses in the rat
In rats, AMPH-evoked behavioral sensitization has been measured as increases in locomotor
behavior (Ikemoto, 2002). In addition, stereotypy behaviors such as repetitive head movements,
sniffing, oral movements and blinking rate, have been observed in animal models of sensitization
(Robinson and Berridge, 2001; Tanimura et al., 2009). It has been postulated that the
accompanying alterations in AMPH-stimulated DA overflow may promote drug seeking behaviors
(Eiden & Weihe, 2011). Additionally, psychostimulants such as AMPH produce interoceptive cues
previously shown to serve as conditioned stimuli, and these interoceptive discriminant cues could
produce sensitized behavioral responses (Fontana et al., 1993). Clearly, neural changes that
mediate conditioned behavior in the absence of drug must be understood to fully address how brain
changes contribute to the enduring drug-seeking in addiction.
Discriminant cue-evoked responses (cross-sensitization)
Neurochemical sensitization due to previous drug exposure is characterized by an increase in
dopamine release through exocytosis or AMPH-evoked DA overflow beyond amounts released
before sensitization occurs. The literature shows that these two mechanisms are altered in animal
models of drug addiction (Elden and Weihe, 2011). Moreover, DA release is evoked when animals
are placed in the presence of conditioned drug-paired stimuli (Post et al., 1980), in the drug-paired
chamber of a conditioned place preference paradigm, (Duvachelle et al., 2000; Duvachelle et al.,
2000) or in the presence of discriminant cues of a self-administration model (Ito et al., 2000); but
not in a neutral environment.
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EXPERIMENTAL HYPOTHESIS
An extant literature supports the idea for sensitization of DA release, both via AMPH-mediated
mechanisms at DAT (Fordahl et al. 2016, Callipari et al., 2014, Hayashizaki et al., 2013) and
VMAT (Daberkow et al., 2013; Wang et al., 1997, Takahasi et al., 1997) and through Discriminant
Cue-mediated mechanisms. Unfortunately, it seems that the sensitized (i.e., enhanced)
release/exocytosis has been accepted as an explanatory mechanism for too long because the precise
neural mechanisms which produce sensitized DA overflow have not been consistently pursued
(Fontana et al., 1993).

Experimental studies of DA release have only measured an

epiphenomenon; that is, measures of extracellular DA do not constitute a mechanism. In contrast,
there is a dearth of research exploring the mechanism(s) by which presynaptic regulation of DA
overflow becomes sensitized. It is parsimonious to predict that such a mechanism must explain
sensitization observed through both mechanisms of release – the diffusion/exchange mechanism
that involves AMPH and exocytosis that mediates normal neurotransmission in response to
exteroceptive or interoceptive cues. On the other hand, it could be that sensitization involves two
independent mechanisms modulating sensitization of the diffusion/exchange and exocytosis
mechanisms. For example, in response to AMPH, DA overflow might be sensitized by changes in
DA transporter function (Ingram et al., 2002) but sensitized DA release produced by exocytosis
might be mediated by changes in vesicular docking proteins, such as synaptotagmin or syntaxin
(Sokolov et al., 2003). In this study, the working hypothesis is that neuronal sensitization is
produced by changes in VMAT function that accelerates redistribution of DA between vesicular
and cytoplasmic DA pools based on demand. It is predicted that blocking VMAT function during
AMPH exposure will block sensitization of behavior evoked by AMPH stimulation and
depolarizing electrical stimulation.
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RESEARCH AIMS
Aim 1. The Role of VMAT Blockade in AMPH-Evoked Rotational Behavior
It is predicted that AMPH alters VMAT activity to produce sensitized behavioral responses to a
subsequent AMPH challenge. To test this, rats with unilateral nigrostriatal DA lesions will be
pretreated with Tetrabenazine (TBZ), a VMAT blocker (Randal et al., 2014), immediately before
each administration of a sensitizing regimen of AMPH injections to test whether AMPH- evoked
behavioral sensitization is prevented. TBZ was selected for this study because it is more selective
than reserpine (Yao et al., 2011; Roberts et al.,1 986; Yero & Rey, 2008). After an incubation
period (7 days after the last sensitizing challenge of AMPH), AMPH-evoked rotational behavior
will be used to test whether preventing access of AMPH to VMAT attenuates behavioral
sensitization mediated by AMPH-evoked DA release.
Aim 2. The Role of VMAT blockade in Electrical Stimulated Rotational Behavior
It is predicted that AMPH alters VMAT function to produce sensitized behavioral responses
mediated by depolarization-induced vesicular-based DA release. To test this, rats implanted with
an electrode in the nigrostriatal bundle will be pretreated with TBZ, a VMAT blocker, during a
sensitizing regimen of AMPH injections to test whether behavioral sensitization is prevented. After
an incubation period (7 days after the last sensitizing challenge of AMPH), electrical stimulated
rotational behavior (ESRB) will be measured to test behaviors that reflect depolarizing DA release
through exocytotic-like mechanisms (Grant et al., 2020).
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MATERIALS AND METHODS
Subjects. Male Wistar rats (300-350g; Envigo, Indianapolis, IN, USA) were pair-housed in the
in Individual Ventilated Cages (IVC) (460 x 270 x 230 cm, floor area: 800 cm2) with food and
water ad libitum. The colony room is temperature-controlled on a 12:12 h light/dark cycle (lights
on at 07:00 h). All procedures were approved by the University of Texas at El Paso Institutional
Animal Care and Use Committee (IACUC) in accordance with all federal and institutional
guidelines.
Drugs and chemicals. D-Amphetamine, Tetrabenazine, and 6-hydroxydopamine (6-OHDA
hydrobromide) were obtained from Sigma Aldrich (St. Louis, MO, USA). D-Amphetamine was
dissolved in a vehicle solution of 0.9% saline. 6-OHDA was dissolved in a vehicle solution of
0.9% saline and ascorbic acid. Finally, Tetrabenazine was dissolved in a vehicle solution of 0.9%
saline and Hydrochloric acid was added to adjust the pH to 3.4-4.0. All doses for Tetrabenazine
were selected based on previous work shown in Table 1, doses higher than 2.0 mg/kg have been
shown to severely reduced locomotion and induce deep sedation (Owenson-White et al., 2012).
All injections were administered intraperitoneally (IP) except for 6-OHDA, which was
microinfused intracranially. Drug doses are as follow: SAL (1.0 ml/kg), AMPH (1.5 mg/kg),
Low dose TBZ (0.5 mg/kg) and High dose TBZ (1.75 mg/kg).
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Table 1: Tetrabenazine doses used in rodent models.
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Aim 1. The Role of VMAT Blockade in AMPH-Evoked Rotational Behavior

Table 2: Experimental groups used for Aim 1.

Animals were randomly assigned to six different groups based on drug treatments: 1) saline
(SAL)/SAL, 2) Low TBZ/SAL, 3) High TBZ/SAL, 4) SAL/AMPH, 5) Low TBZ/AMPH, 6)
High TBZ/AMPH. Table 2 shows sample sizes for each group in this study.

Experimental Groups
Control Group
Pretreatment

Sensitized Group

Control Treatment

Pretreatment

Sensitizing Treatment

SAL

SAL

8

SAL

AMPH

8

Low TBZ

SAL

9

Low TBZ

AMPH

12

High TBZ

SAL

8

High TBZ

AMPH

10

Table 3: Experimental timeline.
This timeline illustrates the seven procedural phases in the experimental design. and described in
detail below.
Sensitization of AMPH-Evoked Rotational Behavior
5 Days
3 Days of
14 Days
7 Days
7 Days
Surgery
Animal
6-OHDA
Recovery
AMPH
Incubation
Handling Infusions
Sensitization
Period
Regimen

1 Day

2 Days

Expression
of
Sensitization

Tissue
Assay &
HPLC

Handling.
Animals were handled daily for 10-15 minutes across five consecutive days to allow the animals
to habituate to the experimenter.
Surgery: Unilateral 6-OHDA Infusion.
9

Animals were anesthetized with Isoflurane (IsoSol, VEDCO) and placed in a stereotaxic
apparatus. 6-OHDA (10µg/2µl) was injected unilaterally into the Substantia Nigra Pars Compacta
(SNc) using a 30-gauge stainless steel guide cannula in the following coordinates: P -5.0 mm, L ±
2.0 mm, V -7.4 mm relative to bregma. The left or right hemisphere was randomly selected for
microinfusion. Rats were left in their home cages for two weeks to allow time for the neurotoxic
effects of 6-OHDA to develop, during this time animals were monitored daily.
AMPH Sensitization Regimen.
During the 7-day sensitization period, animals were assessed on rotational behavior in rotometers
(San Diego Instruments). These consisted of round Plexiglass bowls with a floor diameter of 20
cm, a lip diameter of 45 cm and 15 cm tall. A vest was wrapped around the torso and connected to
a stiff cable attached to an infrared/photo diode counter 71 cm above the test floor which
automatically counts rotational behavior. Quarter turns in each direction were counted in 5 min
time bins by computer. Specifically, contraversive rotational behavior was measured as 90o turns
away from the intact side. Based on group assignment animals received an initial dose of either
SAL (1 ml/kg, i.p) or TBZ (0.5 mg.kg, i.p or 1.75 mg/kg, i.p), then immediately placed in a
rotometer for 30 min. Thereafter, rats received injections of AMPH (1.5 mg/kg, i.p) or SAL and
replaced into the rotometers for 2 hours.
Incubation Period.
Rats remained in their home cages for seven days following the last sensitization treatment.
Expression of Sensitization.
After a 7-day incubation period in which animals were left undisturbed in their cages, rats
underwent an AMPH challenge day to test for behavioral sensitization of rotational behavior.
During the challenge, all animals from all four groups were placed into the rotometers, and as
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before, received an AMPH injection regardless of group and were placed in the rotometer
chambers for behavioral testing.
Post-mortem Measures of Neostriatal Catecholamine Levels.
After the challenge day, animals were allowed a washout period for 7 to 8 days to ensure there
were no drugs in their system before tissue preparation. On the day of the tissue assay, animals
were decapitated while awake and striatal tissue from both hemispheres was harvested and
prepared for tissue analysis using High-Pressure Liquid Chromatography coupled with
Electrochemical Detection (HPLC-EC). HPLC-EC parameters were optimized to measure DA
and its metabolites DOPAC and HVA. These data were used to corroborate that dopamine
depletions were sufficient for our unilateral 6-OHDA animal preparation. The a priori criterion
required for inclusion was at least a 30% DA depletion, thus, animals with a percent depletion
smaller than 30% were excluded from the study.
Statistical Analyses.
Aim 1. The Role of VMAT Blockade in AMPH-Evoked Rotational Behavior
Statistical analyses were conducted using PrismTM (GraphPad software v6) and IBM SPSS
Statistics (software v24). For behavioral and neurochemical data, analyses included one-way,
two-way and repeated measures ANOVAs. The Greenhouse-Geisser correction was used if
violations to sphericity were found. If significant differences were found, post hoc analyses
included Tukey pairwise comparisons.
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Aim 2. The Role of VMAT Blockade in Electrical Stimulated Rotational Behavior
For aim 2, sensitization of exocytotic-like DA release was explored using electrical stimulation
that evokes mesostriatal DA release and rotational behavior (Grant et al., 2020).
Table 4: Experimental groups used for Aim 2.
Animals were randomly assigned into four different groups based on drug treatments: 1) saline
(SAL)/SAL, 2) TBZ (1.75 mg/kg)/SAL, 3) SAL/AMPH, 4) TBZ/AMPH. Table 4 shows sample
sizes for each group in this study.
Experimental Groups
Control Group
Pretreatment

Sensitized Group

Control Treatment

Pretreatment

Sensitizing Treatment

SAL

SAL

11

SAL

AMPH

13

TBZ

SAL

10

TBZ

AMPH

13

Table 5: Experimental timeline.
This timeline illustrates the eight procedural phases in the experimental design and described in
detail below.
Sensitization of Electrical Stimulation - Evoked Rotational Behavior
5 Days

4 Days of
Surgery

7 Days

5 Days

7 Days

7 Days

1 Day

2 Days

Animal
Handling

Electrode
Implantation

Recovery

A Priori ESRB
Validation

AMPH
Sensitization
Regimen

Incubation
Period

Expression
of
Sensitization

Tissue
Assay

Handling.
Animals were handled daily for 10-15 minutes across five consecutive days to allow the animals
to habituate to the experimenter.
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Stereotaxic Implantation of Bipolar Electrodes.
Following acclimatation to the vivarium, rats were anesthetized with Isoflurane (IsoSol, VEDCO)
and placed in stereotaxic apparatus. Animals received bipolar twisted, stainless steel electrodes
(0.125 mm diameter wires, Plastics One, MS303/3-B) implanted into the Medial Forebrain Bundle.
Coordinates are as followed: P -3.00 mm, L ± 1.8, V -8.4 mm relative to bregma. Bilateral implants
were utilized to increase the likelihood of successful implantation that evokes reliable ESRB. Rats
were monitored for uneventful recovery daily for 7 days following surgery.
A Priori Criterion for ESRB.
Immediately after recovery, animals were tested across five consecutive days to validate electrode
implantation into the MFB. Animals were placed into a Plexiglas test chamber (45.7 cm x 35.6 cm
x 27.9 cm) and fastened to electrical commutators (Plastics One,SL2C) via 50 cm spring-covered
bipolar cables (Plastics One, Model 305-305 TT2 CS) used to deliver the stimulus. Animals
received electrical stimulation (unilateral monophasic rectangular pulses, 0.1 msec pulse duration,
10 sec train duration) aimed at the MFB through an A-M systems 2100 Isolated Pulse Stimulator.
Pulses were delivered in an ascending order of intensity (50, 100, 150, 200, 250, and 300 µA) with
120 sec inter-stimulus intervals. To determine optimal behavioral responses, both positive and
negative polarities were tested within each hemisphere. ESRB rotations were recorded as 90 o turns
contraversive to the stimulated hemisphere. An a priori criterion of a minimum 8 quarter turns at
the highest intensity (300 µA) in 10 sec was required for inclusion in the experiment, otherwise
animals were culled.
AMPH Sensitization Regimen.
During the 7-day sensitization period, animals were assessed in the rotometers as described in
Aim 1. Quarter turns in each direction were counted in 5 min time bins; however, because animals
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were intact (i.e., no unilateral DA depletion) locomotion was quantified as the sum of 90 o turns in
both directions. Based on group assignment animals received an initial dose of either SAL (1
ml/kg, i.p) or TBZ (1.75 mg/kg, i.p), then immediately placed in a rotometer for 30 min.
Thereafter, rats received injections of AMPH (1.5 mg/kg, i.p) or SAL and replaced into the
rotometers for 2 hours.
Incubation Period.
Rats remained in their home cages for seven days following the last sensitization treatment.
Expression of Sensitization.
After the incubation period, animals were tested for ESRB across the 6-intensities as during the 5day a priori testing phase. However, for this test of expression, animals were placed into the
rotometer chambers that served as the conditioning environment during the sensitization regimen
of AMPH treatment. To avoid a ceiling effect, each rat was tested with an additional specific
intensity (µA) predicted to produce 50% of the maximum turns based on a linear regression
constructed from the individual a priori data for each rat.
Histological Assessment of Electrode Implantation.
After testing was complete, animals received a lethal dose of sodium pentobarbital (100 mg/kg,
i.p). Perfusions were then performed for tissue collection by opening the chest cavity, and a canula
was inserted into the left ventricle pumping 0.9 % saline followed by 4% paraformaldehyde
solution. The brain was harvested and stored in 30% sucrose for cryoprotection. The brains were
cut in a coronal plane in 40 µm sections using a Leica microtome. Brain sections were stained with
Cresyl Violet to verify electrode placement into the MFB.
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Aim 2. The Role of VMAT Blockade in Electrical Stimulated Rotational Behavior
Statistical analyses were conducted using PrismTM (GraphPad software v6) and IBM SPSS
Statistics (software v24). For histological data, analyses included Pearson correlation coefficient
and A Chi Square test. For behavioral data, analyses included one-way, two-way, and repeated
measures ANOVAs. The Greenhouse-Geisser correction was used if violations to sphericity
were present. A Kruskal-Wallis test was performed on locomotion data due to violations of
sphericity. If significant differences were found, post hoc Tukey pairwise comparisons were
conducted.
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RESULTS
Aim 1. The Effect of VMAT Blockade Upon AMPH-Evoked Rotational Behavior During
the Induction Phase of Sensitization.
Post-Mortem Measures of Striatal Catecholamine Levels.
Catecholamine brain levels were calculated as ng/mg wet brain tissue and subsequently the 6OHDA-treated hemisphere levels were expressed as percent depletion relative to the intact
hemisphere (Table 6). Rats that did not have a DA percent depletion of at least 30% were
excluded from analysis, our a priori criterion. One-way ANOVAS were used to compare the
amount of depletion for DA, DOPAC and HVA, respectively, across the 6 groups. There was no
significant difference in the amount of DA, DOPAC and HVA depletion between all 6 groups
[F’s(5,54)≤ 1.40, p’s≥0.05] . Because there were no significant differences in lesion size between
groups this eliminates the possibility for experimental outcomes due to differences in DA
asymmetry.

Table 6: Mean Post-Mortem DA and Metabolite Tissue Levels and Percent Depletions.
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AMPH-Evoked Rotational Behavior.
During the induction phase it is likely that VMAT blockade impacts the acute behavioral
response to repeated AMPH treatment. To evaluate this possibility, a one-way ANOVA was
performed to determine group differences in AMPH-evoked rotational behavior on Day 1 and
Day 7 of the sensitizing treatments.
Baseline: Induction Phase.
A one-way ANOVA was performed to compare the rotational behavior recorded during the 30minute baseline after animals received a dose of SAL (1.0 mg/kg) or TBZ (0.5 mg/kg; 1.75
mg/kg). On day 1 of induction phase, there was no significant difference between the amount of
turning across the 6 groups, F(5,49)=1.751, p≥0.05 (Figure 1). On day 7 of induction phase, a
significant difference between groups was found; F(5,49)= 4.175, p<0.05; post hoc comparisons,
p<0.05, post hoc comparisons show an increase in rotational behavior in the SAL+AMPH group
compared to the 1.75 TBZ+SAL, 0.5 TBZ+AMPH and 1.75 TBZ+AMPH (Figure 2).
A two-way ANOVA was conducted to compare D1 vs D7 within groups, significant differences
were found; F(5,49)=3.439, p<0.05; post hoc comparisons, p<0.05. Post hoc comparisons
showed a significant decrease in locomotion behavior from D1 to D7 in all groups except for the
SAL+AMPH group (Figure 3).
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Figure 1: Induction Phase D1 (Baseline)

Figure 2: Induction Phase D7 (Baseline)

Figure 3: D1 vs D7 Comparison (Baseline)
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Baseline: Expression Phase.
A one-way ANOVA was performed comparing the rotational behavior during baseline across the
groups, no significant differences were found; F(5,49)=1.440, p>0.05 (Figure 4).

Figure 4: Expression Phase (Baseline)
Total AMPH-Evoked Contraversive Rotational Behavior: Induction Phase.
After a 30-minute baseline, AMPH-evoked contraversive rotational behavior was recorded for a
2-hour period across 7 days. For D1, a one-way ANOVA conducted across the six groups
demonstrated significant differences in total contraversive turns; F(5,49)=9.608, p<0.05 (Figure
5). Specifically, there was a significant increase in the total number of contraversive quarter turns
in the SAL+AMPH group compared to the three control groups (SAL+SAL, 0.5 TBZ+SAL, 1.75
TBZ+SAL); post hoc pairwise comparisons, p<0.05. There was also a significant reduction in
the average number of AMPH-induced turns in both the 0.5 TBZ+AMPH and 1.75 TBZ+AMPH
groups compared to the SAL+ AMPH group; post hoc pairwise comparison, p<0.05,
demonstrating an acute TBZ effect.
For D7, a one-way ANOVA conducted across the six groups demonstrated significant
differences in total contraversive turns; F(5,49)=15.97, p<0.05 (Figure 6). Specifically, there was
a significant increase in the total number of contraversive quarter turns in the SAL+AMPH group
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compared to the three control groups (SAL+SAL, 0.5 TBZ+SAL, 1.75 TBZ+SAL); post hoc
pairwise comparisons, p<0.05. There was also a significant reduction in the total number of
AMPH-induced turns in both the 0.5 TBZ+AMPH and 1.75 TBZ+AMPH groups compared to
the SAL+ AMPH group; post hoc pairwise comparison, p<0.05, demonstrating an acute TBZ
effect.
A two-way ANOVA comparing the behavioral response of each group between D1 and D7
demonstrated significant differences in total contraversive turns; F(1,7)=26.60, p<0.05 (Figure
7). Specifically, there was a significant increase in the total number of turns for the SAL+AMPH
from D1 to D7 (post hoc pairwise comparison, p<0.05), indicating behavioral sensitization. The
three control groups (SAL+SAL, 0.5 TBZ+SAL, 1.75 TBZ+SAL) displayed no behavioral
activation. In the presence of 0.5 or 1.75 mg/kg TBZ, AMPH-evoked contraversive rotational
behavior did not change between D1 and D7.

Figure 5: Induction Phase D1
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Figure 6: Induction Phase D7

Figure 7: D1 vs D7 Comparison
Time Series Analysis of AMPH-Evoked Contraversive Rotational Behavior: Induction
Phase.
Analyses of time series data permit visualization in three different phases of the AMPH-evoked
response (Ascending phase, Peak and Descending phase) associated with sensitization (Segal &
Schuckit, 1983).
For D1, a repeated measures ANOVA across the time course of the response demonstrated
significant changes, reflected in the initial activation and subsequent decline in the response
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across the two-hour period; F(23,115)=3.58, p<0.05 (Figure 8). There were also differences in
this response across groups, Group F(5, 31)=277.3, p<0.05. Specifically, there was a significant
increase in rotational behavior in the SAL+AMPH group when compared to the control groups
(SAL+SAL, 0.5 TBZ+SAL, 1.75 TBZ+SAL); post hoc comparisons p<0.05, these statistical
outcomes are not shown in Figure 8 to optimize clarity since control groups do not show AMPHevoked behavior. In the presence of TBZ, both the 0.5 TBZ+AMPH and 1.75 TBZ+AMPH
showed a decrease in contraversive rotational behavior across the 2 hours compared to that of the
SAL+AMPH group; post hoc comparisons p’s<0.05.
Data were evaluated by different phases: ascending, peak and descending. On D1 of the
Induction Phase, during the first 30 minutes that constitute the ascending phase, the 0.5
TBZ+AMPH and 1.75 TBZ+AMPH groups showed a decrease in rotational behavior compared
to the SAL+AMPH group except for the first 5-minute interval (pairwise post hoc comparisons,
p’s<0.05). At the Peak response (the 7th 5-minute interval), both TBZ-treated AMPH groups
displayed an attenuation in rotational behavior compared to the SAL+AMPH group (pairwise
post hoc comparisons, p’s<0.05). During the Descending Phase, the SAL+AMPH group showed
a slower rate of decline in rotational behavior compared to both TBZ-treated AMPH (pairwise
post hoc comparisons, p’s<0.05), indicating a prolonged duration.
For D7, a repeated measures ANOVA across the time course of the response demonstrated
significant changes, reflected in the initial activation and subsequent decline in the response
across the two-hour period; F(23,115)=2.31, p≤0.05 (Figure 9). There were also differences in
this response across groups, Group F(5, 31)=552.9, p<0.05.
Specifically, there was a significant increase in rotational behavior in the SAL+AMPH group
when compared to the control groups (SAL+SAL, 0.5 TBZ+SAL, 1.75 TBZ+SAL); post hoc
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comparisons p<0.05, these statistical outcomes are not shown in Figure 9 to optimize clarity
since control groups do not show AMPH-evoked behavior. In the presence of TBZ, both the 0.5
TBZ+AMPH and 1.75 TBZ+AMPH show a contraversive rotational behavior decrease across
the 2 hours compared to that of the SAL+AMPH group; post hoc comparisons p<0.05.
Data were evaluated by different phases: ascending, peak and descending. On D7 of the
Induction Phase, during the first 30 minutes that constitute the ascending phase, the 0.5
TBZ+AMPH and 1.75 TBZ+AMPH groups showed a decrease in rotational behavior compared
to the SAL+AMPH group (pairwise post hoc comparisons, p’s<0.05). Qualitatively, the Peak
response appears to be sustained for a longer time period (i.e., the 6th-13th 5-minute intervals),
both TBZ-treated AMPH groups displayed an attenuation in rotational behavior compared to the
SAL+AMPH group (pairwise post hoc comparisons, p’s<0.05). During the Descending Phase,
the SAL+AMPH group showed a slower rate of decline in rotational behavior compared to both
TBZ-treated AMPH (pairwise post hoc comparisons, p’s<0.05), indicating a prolonged duration.

Figure 8: Induction Phase D1 (Timeline)
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Figure 9: Induction Phase D7 (Timeline)
Time Series Analysis of AMPH-Evoked Contraversive Rotational Behavior: D1 vs D7
Comparison in SAL+AMPH Group.
Behavioral sensitization was observed when comparing the amount of AMPH-evoked rotational
behavior for D1 vs D7 in the SAL+AMPH group; F(23,161)=6.380, p<0.05 (Figure 10). During
the first 30 minutes of the Ascending Phase there is no significant difference between the two
days. On D7, there was a significant increase in rotational behavior in the Peak Phase (i.e., the 6th
5-min interval) but not the rest of the Peak Phase (intervals 6-13). For the Descending Phase,
there is a significant increase in rotational behavior on D7, indicating prolonged duration of
AMPH effects related to sensitization.
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Figure 10: Induction Phase D1 vs D7 (Aim 1)
Blockade of Expression During a Challenge Test. VMAT Pretreatment During
Sensitization Blocks Expression.
Seven days after the Induction Phase, animals were tested for blockade of sensitization by TBZ
pretreatment. During this challenge test all six groups received AMPH.
A one-way ANOVA comparing AMPH-evoked rotational behavior across all groups
demonstrated a significant difference in total contraversive turns; F(5,49)=6.98, p<0.05 (Figure
11). Specifically, there was a significant increase in the total number of contraversive turns in the
SAL+AMPH group compared to the three control groups (post hoc pairwise comparisons,
p<0.05), indicating behavioral sensitization. Further, rotational behavior in both TBZ-treated
AMPH groups showed a significant decrease in AMPH-evoked rotational behavior compared to
the SAL+AMPH group (post hoc pairwise comparisons, p<0.05), indicating blockade of
sensitization.
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Figure 11: Expression of Sensitization
Time Series Analysis of AMPH-Evoked Contraversive Rotational Behavior: Expression
Phase.
For Challenge day, a repeated measures ANOVA demonstrated a significant difference between
contraversive rotational behavior across the 6 groups during the two-hour period; F’s(23,115)≥
25.85, p≤0.05 (Figure 12). Specifically, there was a significant increase in rotational behavior in
the SAL+AMPH group when compared to the control groups (SAL+SAL, 0.5 TBZ+SAL, 1.75
TBZ+SAL); post hoc comparisons p<0.05, these statistical outcomes are not shown in Figure 12
to optimize clarity since control groups do not show AMPH-evoked behavior. In the presence of
TBZ both the 0.5 TBZ+AMPH and 1.75 TBZ+AMPH show an overall decrease in contraversive
rotational behavior across the 2 hours compared to that of the SAL+AMPH group; post hoc
comparisons p<0.05. On Challenge day, during the first 40 minutes that constitute the ascending
phase, the three control groups showed a decrease in rotational behavior compared to the
SAL+AMPH group, both the 0.5 TBZ+AMPH and 1.75 TBZ+AMPH groups showed a decrease
in rotational behavior compared to the SAL+AMPH group only during the first 10 minutes of
this phase (pairwise post hoc comparisons, p’s<0.05). At the Peak response (the 9th 5-minute
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interval), both TBZ-treated AMPH groups displayed an attenuation in rotational behavior
compared to the SAL+AMPH group (pairwise post hoc comparisons, p’s<0.05). During the
Descending Phase, the SAL+AMPH group showed a slower rate of decline in rotational behavior
compared to both TBZ-treated AMPH (pairwise post hoc comparisons, p’s<0.05), indicating a
prolonged duration.

Figure 12: Expression of Sensitization (Timeline)
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Aim 2. The Role of VMAT blockade in Electrical Stimulated Rotational Behavior.
Electrode Implantation Verification.
Histology to validate electrode placement into the MFB was conducted using Nissl-stained
coronal brain sections. An ordinal scale was created indicating distance from the target zone as
defined in Figure 13. Animals with distances greater than this range were culled from the
experiment; these animals failed to display ESRB.
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Bregma -4.08

Figure 13. Histological locus of electrodes implanted in the MFB. Legend below shows A) An
ordinal scale created to measure distance between MFB and tip of electrode. B) Four different
symbols representing the different groups in the experiment. One electrode placement was
located in the SNc, -4.80 mm from Bregma (Figure not shown).

A Priori Analysis: Electrode Location and Turning Behavior.
A Pearson’s correlation coefficient analysis was run to compare electrode placement (distance
from targeted MFB) with (1) the average ESRB across the 5 days during A priori testing and (2)
ESRB during the Challenge Day across 100𝜇𝜇𝜇𝜇 − 300𝜇𝜇𝜇𝜇. There was no significant correlation

for A Priori data at 50𝜇𝜇𝜇𝜇 and 100𝜇𝜇𝜇𝜇 (r= -0.17 and -0.20 respectively, p’s>0.05). In contrast, A
Priori data ranging from 150𝜇𝜇𝜇𝜇-300𝜇𝜇𝜇𝜇, displayed significant correlations (r’s= -0.33 to -0.52,
p’s<0.05). The correlations for the Challenge Day ranged between r= -0.12 to r= -0.22 for the
50𝜇𝜇𝜇𝜇-150𝜇𝜇𝜇𝜇 intensities but these correlations were not significant (p’s>0.05). Challenge day
correlations were significant for intensities from 200𝜇𝜇𝜇𝜇-300𝜇𝜇𝜇𝜇 ranged between r= -0.31 to r= 0.41, p’s<0.05). It is important to note that all the animals used in the analysis had already met
our a priori criteria of a minimum number of turns at the highest intensity (300𝜇𝜇𝜇𝜇), which most
likely contributes to a flattening of the regression curve.
A Priori Analysis: Electrode Location and Group Placement.
A Chi Square Goodness of Fit analysis was conducted to test for differences between electrode
placement across all groups. There were no significant differences found between location of
electrode and animal group placement X2 (30, N=42)= 35.00, p>0.05.
A Priori Analysis: Electrical Stimulation Across 5 Days.
A repeated measures two-way ANOVA was conducted to see if electrical stimulation is
sensitizing, the analysis compared rotational behavior of all animals (data was collected before
animals were assigned to each group) on all intensities (50𝜇𝜇𝜇𝜇 − 300𝜇𝜇𝜇𝜇) across a 5-day period.
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There was no significant difference found in the amount of turning behavior across the 5 days;
F(20,1104)=1.170, p>0.05 (Figure 14). This analysis also shows us that higher intensities such as
250 𝜇𝜇𝜇𝜇 and 300 𝜇𝜇𝜇𝜇 do not show significant increases in electrical stimulated rotational behavior;
F(5,276)=32.33, p< 0.05. These results suggest a ceiling effect at these higher intensities.

Figure 14: Electrical Stimulation Across 5 Days
Baseline: Induction Phase.
For D1 of the induction phase, a one-way ANOVA conducted across the four groups showed no
significant differences in total locomotor behavior during the 30-minute baseline; F(3,28)=1.19,
p>0.05 (Figure 15). For D7 of induction phase, a one-way ANOVA conducted across the four
groups showed no significant differences in total locomotor behavior during the 30-minute
baseline; F(3,28)=1.33, p>0.05 (Figure 16). A two-way ANOVA comparing the behavioral
response of each group between D1 and D7 demonstrated significant differences in total
contraversive turns; F(3,28)=64.78, p<0.05 (Figure 17). Specifically, there was a significant
decrease in locomotor behavior from D1 to D7 in all groups except the 1.75 TBZ+SAL group;
post hoc pairwise comparison, p<0.05.
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Figure 15: Induction Phase D1 (Baseline)

Figure 16: Induction Phase D7 (Baseline)

Figure 17: D1 vs D7 (Baseline)
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AMPH-Evoked Locomotion: Induction Phase.
For D1, a Kruskal-Wallis analysis conducted across the four groups demonstrated a significant
difference in total locomotor behavior; H(3)=16.819, p<0.05 (Figure 18). Specifically, there was
a significant increase in locomotor behavior in the SAL+AMPH group when compared to the
control groups (SAL+SAL and 1.75 TBZ+SAL); post hoc comparisons p<0.05. In the presence
of TBZ, the 1.75 TBZ + AMPH group shows no significant difference when compared to the
SAL+AMPH group; post hoc comparison p>0.05.
For D7, a Kruskal-Wallis test across the four groups demonstrated a significant difference in
total locomotor behavior; H(3)=18.739, p<0.05 (Figure 19). Specifically, there was a significant
increase in locomotor behavior in the SAL+AMPH group when compared to the control groups
(SAL+SAL and 1.75 TBZ+SAL); post hoc comparisons p<0.05. In the presence of TBZ, the
1.75 TBZ + AMPH group shows no significant difference when compared to the SAL+AMPH
group; post hoc comparison p>0.05.
A two-way ANOVA comparing the locomotor behavior of each group between D1 and D7
demonstrated no significant differences in the total locomotor behavior; F (3,28)=2.76, p> 0.05
(Figure 20).
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Figure 18: Induction Phase D1

Figure 19: Induction Phase D7

Figure 20: D1 vs D7 Comparison
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Time Series of AMPH-Evoked Locomotion: Induction Phase.
For D1, a repeated measures ANOVA across the time course of the response demonstrated
significant changes, reflected in the initial activation and subsequent decline in the response
across the two-hour period; F(23,644)=6.97, p<0.05 (Figure 21). There were also differences in
this response across groups, Group F (3,28)=11.54,p<0.05. Specifically, there was a significant
increase in total locomotor behavior in the SAL+AMPH group when compared to the control
groups (SAL+SAL and 1.75 TBZ+SAL); post hoc comparisons p<0.05. Differences between
1.75 TBZ+SAL vs SAL+AMPH and 1.75 TBZ+AMPH were found but are not indicated in the
graph for the sake of clarity. On D1 of the Induction Phase, during the first 20 minutes that
constitute the ascending phase, the 1.75 TBZ+AMPH group showed a decrease in rotational
behavior compared to the SAL+AMPH group except for the first 5-minute interval (pairwise
post hoc comparisons, p’s<0.05). At the Peak response (the 6th 5-minute interval), the 1.75
TBZ+AMPH group showed an attenuation in rotational behavior compared to the SAL+AMPH
group (pairwise post hoc comparisons, p’s<0.05). During the Descending phase, the
SAL+AMPH grouped showed a similar rate of decline in rotational behavior compared to the
1.75 TBZ+AMPH (pairwise post hoc comparisons, p’s<0.05).
For D7, a repeated measures ANOVA across the time course of the response demonstrated
significant changes, reflected in the initial activation and subsequent decline in the response
across the two-hour period; F(23,644)=5.47, p<0.05 (Figure 22). There were also differences in
this response across groups, Group F(3,28)=8.242, p<0.05. Specifically, there was a significant
increase in total locomotor behavior in the SAL+AMPH group when compared to the control
groups (SAL+SAL and 1.75 TBZ+SAL); post hoc comparisons p<0.05. On D7 of the Induction
Phase, during the first 25 minutes that constitute the ascending phase, the 1.75 TBZ+AMPH
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group showed no decrease in rotational behavior compared to the SAL+AMPH group (pairwise
post hoc comparisons, p’s>0.05) . At the Peak response (the 6th 5-minute interval), the 1.75
TBZ+AMPH group did not show an attenuation in rotational behavior compared to the
SAL+AMPH group (pairwise post hoc comparisons, p’s>0.05). During the Descending phase,
the SAL+AMPH grouped showed a similar rate of decline in rotational behavior compared to the
1.75 TBZ+AMPH (pairwise post hoc comparisons, p’s>0.05).

Figure 21: Induction Phase D1 (Timeline)

Figure 22: Induction Phase D7 (Timeline)
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Time Series Analysis of AMPH-Evoked Total Locomotor Behavior: D1 vs D7 Comparison
in SAL+AMPH Group.
Behavioral sensitization was not observed when comparing the amount of AMPH-evoked
rotational behavior for D1 vs D7 in the SAL+AMPH group (Figure 23). There was no increase in
rotational behavior from D1 to D7 during the Ascending, Peak and Descending Phase. This
suggests that measuring locomotor sensitization using rotometers may not be possible when
using intact animals.

Figure 23: Induction Phase D1 vs D7 ( Aim 2)
Electrical Stimulated Rotational Behavior: A Priori.
For the a priori validation period, a repeated measures ANOVA demonstrated no significant
differences in the amount of electrical stimulated rotational behavior across all four groups; F’s
(3,40)≤0.790, p’s≥0.05 (Figure 24).
Electrical Stimulated Rotational Behavior: Expression Phase.
For the challenge day, a repeated measures ANOVA demonstrated a significant difference
between electrically stimulated rotational behavior across all four groups; F(4,12)=138.3, p<0.05
(Figure 25). Specifically, in the 100 μA intensity, there was a significant increase in total
locomotor behavior in the SAL+AMPH group when compared to SAL+SAL group; post hoc
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comparisons p<0.05. A significant decrease in rotational behavior was found in the 1.75
TBZ+AMPH when compared to the SAL+AMPH group. In the 150 μA intensity, a significant
increase in rotational behavior was found in the SAL+AMPH group when compared to the
SAL+SAL group; post hoc comparisons p<0.05. A significant decrease in rotational behavior
was found in the 1.75 TBZ+AMPH when compared to the SAL+AMPH group; post hoc
comparisons, p<0.05. The reduction of electrical stimulated rotational behavior found in the 1.75
TBZ+AMPH group shows blockade of sensitized behavior in rats that received a pretreatment of
TBZ.

Figure 24: A Priori Rotational Behavior

Figure 25: Expression of Sensitization
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DISCUSSION
In this study, the effect of blocking access by AMPH to VMAT with pretreatment of the VMAT
inhibitor TBZ upon behavioral sensitization was examined in the response to AMPH-evoked
rotational behavior (Aim 1) and electrical stimulation that activates exocytosis-dependent
behavior, Electrically Stimulated Rotational Behavior (ESRB; Aim 2). These behaviors were
examined during two phases: (1) the Induction Phase, when a sensitizing regimen of AMPH
treatment was given and where some animals received pretreatment to block access by AMPH to
VMAT; and (2) the Expression Phase, when animals were given either a challenge dose of
AMPH (Aim 1) or tested for ESRB (Aim 2) to evaluate the long-term effects of VMAT blockade
during the sensitization regimen of AMPH. It was found that AMPH-evoked rotational behavior
and ESRB display sensitization that is attenuated by VMAT blockade. These results are
significant because they suggest a common mechanism that mediates the expression of both a
pharmacokinetic-driven and exocytotic-like driven behaviors, with a locus at VMAT function.
Previous research has demonstrated that behavioral sensitization to AMPH-evoked behaviors and
conditioned place preference and self-administration contexts are accompanied by sensitization
of DA overflow (Duvachelle et al., 2000; Ito et al., 2000). Therefore, it is important to
understand what presynaptic mechanism drives sensitization in response to a pharmacological
challenge and to conditioned environmental cues or whether there might be different
mechanisms for pharmacologically induced overflow versus exocytotic mechanisms.
It is likely that increases in synthesis rates of DA, increases in DA content or autoreceptor
subsensitivity could account for sensitization of DA release, but an early review of these
mechanisms did not find consistent evidence supporting changes in these mechanisms (Robinson
& Becker, 1986). It could also be that sensitization of AMPH-evoked DA overflow and
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accompanying behavioral responses could be mediated by DAT, but Robinson and Becker
(1986) did not find consistent evidence in support of this idea. Thus, it seems prudent to
understand how sensitization of DA overflow manifests, especially since enhancements in
extracellular DA levels estimated by neuroscience techniques, such as in vivo intracerebral
microdialysis and voltammetry/chronoamperometry are phenomenological measures, as they
provide no insight about causative presynaptic mechanisms.
AMPH is known to reverse the function of the DA transporter to create DA overflow largely
from the intraneuronal cytoplasmic pool. In contrast, exocytosis of DA in response to
environmental cues involves depolarization of axons that is sodium-dependent, leading to
calcium-dependent docking of vesicles to release DA. It was predicted that a single mechanism
could be neuroplasticity at the locus of VMAT, which largely is responsible for storing DA into
vesicles but is also known to play a role in maintaining an equilibrium between DA levels in the
cytoplasmic pool and the vesicular pool (Lohr et al., 2017). Thus, we tested the Redistribution
Hypothesis which predicts VMAT function undergoes a functional change to facilitate
redistribution between these two intraneuronal pools after sensitization based on
pharmacological demand for overflow mediated by the DA transporter or exocytosis in response
to drug-conditioned environmental cues (Duvauchelle et al., 2000; Post et al., 1980). The
present results provide behavioral data supporting the hypothesis for a VMAT-mediated
mechanism that explains sensitization via two mechanisms mediating DA overflow.
Pharmacological Versus Depolarizing Stimulation (Physiological) of Rotational Behavior.
It is important to consider how the pharmacological effects of AMPH stimulation are different
from the physiological activation evoked by electrical stimulation (Grant et al., 2020). The 1.5
mg/kg dose of AMPH used in the present study has been used extensively (Sharp et al., 1987;
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Bardo et al., 1995) and produces a 600-800% increase of extracellular DA. In contrast, previous
research has shown that extracellular levels of DA increase only by 40-50% in response to drugpaired stimuli (Duvauchelle et al., 2000, Kuczenski & Segal, 1989). These increases in response
to environmental stimuli likely reflect physiologically meaningful DA release during neural
communication. We have recently shown that the parameters of electrical stimulation utilized in
this present study increase DA by 25-50%, well within the range of physiologically relevant
activation (Grant et al., 2020). Furthermore, Grant et al. (2020) showed that these parameters of
electrical stimulation produce frequency- and intensity-dependent ESRB and DA overflow that is
sensitive to sodium channel blockade and calcium availability, thus mimicking activation of
exocytotic-like DA overflow. Therefore, it is likely that we are investigating two different
mechanisms involved in evoking DA overflow – reversal of DAT function by AMPH and
exocytotic mechanisms with electrical stimulation. The present results are important because
they provide the basis for future research exploring the neural effects of VMAT blockade during
sensitization procedures.
Induction Phase – Acute Effects of VMAT Blockade During AMPH Treatment
During the 7-day sensitizing treatment, the induction of sensitization cannot directly be evaluated
in animals that are pretreated with TBZ before receiving AMPH. Nonetheless, we found a
reduction in AMPH-induced locomotor behavior due to the acute effects of TBZ present during
the AMPH sensitizing treatment. Parceling the AMPH-evoked behavioral responses across
ascending, peak and descending phases reveals interesting disconnection between measures in
unilateral DA-depleted animals versus intact rats, VMAT blockade decreased locomotion,
measured as AMPH-evoked rotational behavior in unilateral DA-depleted rats (Aim 1) and
locomotor activity (total turns = number of left + right turns) from intact animals (Aim 2), in the
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Ascending Phase. Differences in the responses from unilateral DA-depleted rats and intact rats
become evident in the Peak Phase. Although locomotion in both groups was decreased by
blocking VMAT on the first day of AMPH treatment, by the seventh day of AMPH treatment the
Peak response of AMPH-evoked rotational behavior continued to display a reduction in
comparison to AMPH stimulation alone in the unilateral preparation but locomotor activity from
intact rats was not attenuated by AMPH. Finally, during the Descending Phase of the AMPH
response, AMPH-evoked rotational behavior was consistently decreased by VMAT blockade but
locomotor activation from intact rats was not diminished following the first and last AMPH
treatment. These differences in the behavioral response to AMPH evoked in a unilateral DAdepleted rat versus intact animals bears contemplating that measures of rotational behavior are
not adequate to assess expression of AMPH sensitization, which is discussed next.
Induction Phase – Comparisons Between Unilateral DA-depleted Versus Intact Rats of
AMPH-Evoked Locomotion: Rotometers Are Sometimes Not Adequate.
Our findings show that the unilateral preparation demonstrates sensitization based on its largely
asymmetrical motor response to AMPH, but intact animals did not show sensitization in the
rotometers. It is well known that intact animals do not show the same profile of sensitization as
rats with unilateral lesions. For example, Kuczenski and Segal (1989) have shown that animals
with intact hemispheres rapidly transition from an initial locomotor response to AMPH to
stereotypy, and that across sensitization stereotypy becomes predominant to the exclusion of the
locomotor response. Thus, the present study provides validation that rotometers cannot be relied
upon to evaluate sensitization to stimulant-induced locomotion. Moreover, Castañeda et al.
(2005) showed that using rotometry to estimate behavioral recovery as an assessment of efficacy
of transgenic treatment in a hemi-Parkinsonian rodent model is dissociated from assessments that
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involve neurologically relevant sensory and motor behavioral tests. In the present study, we are
confident that intact animals in the second experiment were sensitized but that we did not use an
adequate approach for intact animals. It is recommended that future studies that utilize intact rats
do not use automated rotometry to study behavioral sensitization.
Expression Phase - Long Term Effects of VMAT Blockade During AMPH Treatment.
The strength of this study is the demonstration of long-term suppression in the expression of
AMPH sensitization by blocking VMAT with TBZ pretreatment. These results support the
hypothesis that neuronal sensitization is produced by changes in VMAT function that accelerates
redistribution of DA between vesicular and cytoplasmic DA pools based on demand. TBZ
pretreatment before AMPH administration during a sensitization schedule prevented behavioral
sensitization of two different types of behavior: 1) AMPH-evoked behavior largely mediated by
the DA Transporter and 2) electrically evoked behavior putatively mediated by exocytotic
mechanisms (Grant et al. 2020). Regarding the latter observation, we only demonstrated
sensitization in the range of 100 μA-150 μA intensities. Our evaluation of the range of
intensities suggests that 50 µA does not evoke a robust response and that intensities higher than
150 µA approach a ceiling effect upon ESRB. These findings support the idea that access of
AMPH to VMAT during induction of sensitization is crucial to develop behavioral sensitization.
It is prudent for future research that aims to develop pharmacotherapeutic treatment for stimulant
drug abuse to evaluate mechanisms governing VMAT function.
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